Roger Dansey, Seagen interim CEO

Seagen se­cures a speedy FDA re­view on Tukysa as Mer­ck buy­out talks re­port­ed­ly stall

Af­ter ru­mors of stalled buy­out talks be­tween Mer­ck and Seagen, per­haps a new Tukysa in­di­ca­tion could reignite in­ter­est.

The FDA has grant­ed Tukysa a pri­or­i­ty re­view in com­bi­na­tion with Genen­tech’s Her­ceptin for sec­ond-line HER2-pos­i­tive metasta­t­ic col­orec­tal can­cer, the com­pa­ny re­vealed on Mon­day. The de­ci­sion comes just a cou­ple of months af­ter Seagen un­corked the full Phase II re­sults at ES­MO, boast­ing a no­table im­prove­ment in over­all sur­vival from the last read­out.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.